Piramal Pharma Limited
PPLPHARMA.BO
Get informed when a big investor buys or sells
+ FollowMarket Cap$260.87B
Close$
Share Statistics
| Market cap | $260.87 Billion |
|---|---|
| Enterprise Value | - |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.46 |
| Beta | 0.34 |
| Outstanding Shares | 1,322,845,880 |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | -83.07 |
|---|---|
| PEG | 551.34 |
| Price to Sales | 2.85 |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | - |
| Debt to Equity | - |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
July 29, 2026
EPS Estimate
$-0.66
Average shareholder expectationRevenue Estimate
$21.51 B
Average shareholder expectationNext Earnings Call
Expected Date
November 11, 2026
EPS Estimate
$-0.37
Average shareholder expectationRevenue Estimate
$23.46 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Piramal Pharma Limited
7,120 employees
CEO: Peter Daniel DeYoung Piramal Pharma Limited operates as a pharmaceutical company in the United States, Europe, Japan, India, and internationally. The company offers a portfolio of pharmaceutical products and services through global development and manufactur...